BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Target Hit|| Long (1Y)
Deutsche Bank initiates Aurobindo Pharma with buy
See consistent growth ahead. Expect faster approvals and market share gains for company. Europe business turnaround is on track. Returns will be driven by strong earnings growth. Expect 18 per cent CAGR in earnings over FY16-18.